Paroxetine Tablet (Extended-Release) bulk supplier for pharma manufacturers

Paroxetine Tablet (Extended-Release) 12.5 mg, 25 mg, 37.5 mg Suppliers & Bulk Manufacturers

Available Forms: Tablet (Extended-Release)

Available Strengths: 12.5 mg, 25 mg, 37.5 mg

Reference Brands: US: Paxil®, Pexeva®, Brisdelle®; EU: Seroxat®, ParoMerck®, Paxetin®

Paroxetine extended-release is a selective serotonin reuptake inhibitor (SSRI) that increases serotonin levels in the brain to improve mood and emotional stability. It is used to treat major depressive disorder, generalized anxiety disorder, social anxiety disorder, and panic disorder, providing sustained symptom relief through its controlled-release formulation for once-daily dosing.

Get Enquiry / Request Bulk Quote

Usually answered within 48 hours | GMP documents shared before you commit

Manufacture or export Paroxetine Tablet (Extended-Release)? List it or send an offer →

Product Description: Paroxetine extended-release tablets are FDA-approved in the USA for treating major depressive disorder (MDD), panic disorder, social anxiety disorder, and generalized anxiety disorder. As a selective serotonin reuptake inhibitor (SSRI), they require a Boxed Warning for increased suicidality risk in young adults, along with compliance to GMP, labeling regulations, and post-marketing surveillance under FDA’s pharmacovigilance programs. In the EU, while immediate-release formulations are more common, extended-release versions must meet EMA or national agency approval standards, including Risk Management Plans (RMPs) and Periodic Safety Update Reports (PSURs). Explore dossier-ready supplies at Pharmatradz.com.

Paroxetine Tablet (Extended-Release) — third party manufacturing & bulk supply

Paroxetine Tablet (Extended-Release) 12.5 mg, 25 mg, 37.5 mg is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:

Wholesale / bulk supply Stock or scheduled supply from an existing manufacturer. The fastest route where the product is already registered in your market.

Third party manufacturing Manufactured to your specification and packed under your own brand and label — suits distributors and brand owners building a portfolio in their market.

Dossier licensing Where a CTD, EU-CTD or ACTD dossier exists it can often be licensed for filing in your name, compressing market entry from years to months.

Indicative minimum order quantity

Paroxetine Tablet (Extended-Release) is supplied as Tablet (Extended-Release) — an oral solid dosage form, so the indicative MOQ is 200,000 units. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market. See full supply terms for dossier formats, market availability and shelf life.

Manufacturers of Paroxetine Tablet (Extended-Release) listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding.

Request a quote for Paroxetine Tablet (Extended-Release) →

Usually answered within 48 hours, with matched manufacturers, indicative prices and document status.

Back to Listing

Frequently Asked Questions

Paroxetine Tablet (Extended-Release) is listed as Tablet (Extended-Release) in 12.5 mg, 25 mg, 37.5 mg. Further strengths and pack presentations are confirmed with the manufacturer at RFQ stage.

Paroxetine Tablet (Extended-Release) is referenced against US: Paxil®, Pexeva®, Brisdelle®; EU: Seroxat®, ParoMerck®, Paxetin®. Reference brands are shown for identification only and remain the property of their respective trademark owners.